Ascendis Pharma Endocrinology Division A/S: Financial statements 2019
CVR: 32323537
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
Ascendis Pharma Endocrinology Division A/S (CVR 32323537) has filed annual accounts for 2019. In 2019, the company reported a gross profit of EUR -89,300,964 and a net result of EUR -95,044,994 compared with EUR -59,159,586 the year before. Equity in the 2019 report amounted to EUR -302,791,193.
- Gross Profit
- EUR -89,300,964
- Profit/Loss
- EUR -95,044,994
- Equity
- EUR -302,791,193
- Total Assets
- EUR 27,804,481
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -89.3M EUR | -95M EUR | -302.8M EUR | 0 |
| 2018 | - | -54.4M EUR | -59.2M EUR | -207.7M EUR | 0 |
| 2017 | - | -57.3M EUR | -60.3M EUR | -148.6M EUR | 0 |
| 2016 | - | -42.3M EUR | -44M EUR | -88.3M EUR | - |
| 2015 | - | -28.8M EUR | -29.6M EUR | -44.3M EUR | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
Ascendis Pharma Endocrinology Division A/S has published its annual report for 2018. Gross profit came to DKK -54,429,523, and the net result was DKK -59,159,586.
About Ascendis Pharma Endocrinology Division A/S
Ascendis Pharma Endocrinology Division A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA, GROWTH DISORDERS DIVISION A/S and ACP 30.06.2012 2 A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported revenue of EUR 140,817,000 and a net result of EUR -38,806,000 compared with EUR -121,118,000 the year before. Equity in the 2025 report amounted to EUR -935,650,000.
